Pre-made Fontolizumab benchmark antibody ( Whole mAb, anti-IFNG therapeutic antibody, Anti-IFG/IFI/IMD69 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Fontolizumab biosimilar, Whole mAb, Anti-IFNG Antibody: Anti-IFG/IFI/IMD69 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease. A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-219-1mg	1mg	3090
GMP-Bios-ab-219-10mg	10mg	Inquiry
GMP-Bios-ab-219-100mg	100mg	Inquiry
GMP-Bios-ab-219-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Fontolizumab biosimilar, Whole mAb, Anti-IFNG Antibody: Anti-IFG/IFI/IMD69 therapeutic antibody
INN Name	Fontolizumab
Target	IFNG
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	1t3f:BA/1t04:DC:BA
95-98% SI Structure	None
Year Proposed	2002
Year Recommended	2003
Companies	PDL BioPharma
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Autoimmune disorders;Crohn's disease;Psoriasis;Rheumatoid arthritis
Development Tech	na